Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038535 | 0.93 | — | — | |
| SCHEMBL9180759 | 0.91 | HTR1A (0.63) | HTR1A | |
| SCHEMBL9176472 | 0.88 | — | — | |
| SCHEMBL9174181 | 0.86 | — | — | |
| SCHEMBL1037297 | 0.83 | — | — | |
| SCHEMBL6635321 | 0.82 | HTR1A (0.47) | HTR1A | |
| SCHEMBL9368508 | 0.81 | HTR1A (0.59) | HTR1A | |
| SCHEMBL9467135 | 0.80 | HTR1A (0.51) | HTR1A | |
| SCHEMBL6634851 | 0.80 | HTR1A (0.48) | HTR1A | |
| SCHEMBL9175474 | 0.80 | HTR1A (0.65) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S | 2002-11-21 | — | — | US | claimed |
| CN-1344265-A | piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2002-04-10 | — | — | CN | claimed |
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| EP-1149087-A1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2001-10-31 | — | — | EP | claimed |
| WO-2000043382-A1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-07-27 | — | — | WO | claimed |
| US-6596722-B2 | Serotonin reuptake inhibitors/HT3 receptor antagonists useful for treatment of depression, psychosis, anxiety disorders, panic disorder, obsessive compulsive disorder, and eating disorders | H. LUNDBECK A/S (DK) | 2003-07-22 | — | — | US | disclosed |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S | 2002-11-21 | — | — | US | disclosed |
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
| EP-1149087-A1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000043382-A1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | HTR1A 51/4885 |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | HTR1A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.